Drug Profile
Research programme: small molecule therapeutics - Aptose Biosciences
Alternative Names: LOR 253 derivatives; LOR-220; LOR-253 oral derivatives; LOR-264; LOR-500; ML-220Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lorus Therapeutics
- Developer Aptose Biosciences
- Class Imidazoles; Indoles; Small molecules
- Mechanism of Action Cell cycle inhibitors; GKLF protein stimulants; MELK protein inhibitors; Signal transduction pathway inhibitors; Transcription factor MTF-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences